Pfizer (PFE, $42.4) and GSK (GSK, $37.09) Are Merging Consumer Healthcare Units
GlaxoSmithKline (GSK) and Pfizer are merging their consumer healthcare businesses.
The two companies’ over-the-counter/consumer healthcare units generated a combined $12.7 billion in sales last year. After the all-equity merger, GSK will own 68% of the joint venture, while Pfizer will hold the rest. The deal is expected to close in the second half of 2019.
Following the merger, GSK plans to spin off the consumer healthcare segment and list it on a London stock exchange within three years, as it plans to focus more on its pharma business. Expecting to save 500 million pounds (about $632 million) by 2022 from the deal, GSK plans to reinvest up to 25 percent of the cost savings into the company's innovation efforts.
For Pfizer, too, the deal should allow more room for the company to concentrate on its prescription drug business from which it makes most of its revenues.
PFE in +2.15% Uptrend, rising for three consecutive days on February 02, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PFE advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on January 02, 2026. You may want to consider a long position or call options on PFE as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on January 08, 2026. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
PFE moved above its 50-day moving average on January 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PFE crossed bullishly above the 50-day moving average on January 08, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 222 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on January 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PFE broke above its upper Bollinger Band on January 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.668) is normal, around the industry mean (9.575). P/E Ratio (20.015) is within average values for comparable stocks, (23.248). PFE's Projected Growth (PEG Ratio) (13.773) is very high in comparison to the industry average of (2.180). PFE's Dividend Yield (0.063) is considerably higher than the industry average of (0.025). P/S Ratio (2.485) is also within normal values, averaging (3.978).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor
Advertisement